In breast cancer cells, gigantol treatment significantly decreased the levels of phosphorylated LRP6, total LRP6 and cytosolic β-catenin, resulting in a decrease in the expression of Wnt target genes Axin2 and Survivin. The gene discussed is LRP6; the disease is breast carcinoma.